Last reviewed · How we verify
Xueshuanxinmaining tablet
Xueshuanxinmaining tablet improves blood circulation and reduces blood stasis through traditional Chinese medicine principles.
Xueshuanxinmaining tablet is a traditional Chinese medicine being evaluated for stable angina pectoris. It has one ongoing Phase 4 trial with no FDA approval. Limited safety data is available.
At a glance
| Generic name | Xueshuanxinmaining tablet |
|---|---|
| Also known as | XSXMN, XSXMN placebo |
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Drug class | Traditional Chinese medicine formulation |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This is a traditional Chinese medicine formulation designed to promote blood flow, remove blood stasis (a key concept in Chinese medicine pathophysiology), and improve microcirculation. The tablet combines multiple herbal ingredients believed to have anticoagulant, antiplatelet, and vasodilatory properties to enhance cardiovascular function and tissue perfusion.
Approved indications
- Cerebral infarction and stroke prevention
- Angina pectoris
- Blood stasis-related cardiovascular conditions
Common side effects
- Gastrointestinal upset
- Bleeding risk (minor)
- Allergic reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: